IMMUCELL CORP /DE/
Current- Director 2025 to present
Skip to record
Executive record
Alpha ID: alpha:person:paul-olivier-te-boekhorstVersion: public-0As of: 2026-10-01
Not yet claimed9 published Claims3 sources
- Director
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
Biography
Mr. te Boekhorst was appointed President, CEO, and Director of ImmuCell in November 2025, bringing over 25 years of leadership experience in animal health. He previously served as an Operating Partner at ARCHIMED and spent 18 years at IDEXX Laboratories, where he led strategy, M&A, and served as Senior Vice President and General Manager of livestock and dairy businesses. Earlier in his career, he worked at The Boston Consulting Group.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Boards
Claims
Executive career
- Dates not publishedExecutive title: President and Chief Executive Officer · Organization not publishedICCC DEF 14A director slate
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
ICCC DEF 14A director slate
sec filing · Source published: Apr 24, 2026 · Retrieved: May 4, 2026
Supports 7 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 4, 2026
- Board role: Board role: Director · Claim reviewed: May 4, 2026
- Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 4, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 4, 2026
- Executive company: Executive at ImmuCell Corporation · Claim reviewed: May 4, 2026
- Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 4, 2026
- Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 4, 2026
Open source
sec proxy · Source published: Apr 24, 2026 · Retrieved: Apr 24, 2026
Supports 1 claim
- Professional Role: Director at IMMUCELL CORP /DE/ · Claim reviewed: May 4, 2026
Open source
public source · Source published: Date unavailable · Retrieved: Date unavailable
Supports 1 claim
- Board membership: Serves on the board of IMMUCELL CORP /DE/ · Claim reviewed: May 4, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-01
- Biography
- published
- Board service
- published
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- not observed
- Background screening
- out of scope